CA3043681A1 - Combination of an egfr t790m inhibitor and a cdk inhibitor for the treatment of non-small cell lung cancer - Google Patents

Combination of an egfr t790m inhibitor and a cdk inhibitor for the treatment of non-small cell lung cancer Download PDF

Info

Publication number
CA3043681A1
CA3043681A1 CA3043681A CA3043681A CA3043681A1 CA 3043681 A1 CA3043681 A1 CA 3043681A1 CA 3043681 A CA3043681 A CA 3043681A CA 3043681 A CA3043681 A CA 3043681A CA 3043681 A1 CA3043681 A1 CA 3043681A1
Authority
CA
Canada
Prior art keywords
lung cancer
small cell
cell lung
egfr
inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA3043681A
Other languages
English (en)
French (fr)
Inventor
Zelanna Iris GOLDBERG
Yuli Wang
Scott Lawrence Weinrich
Keith David Wilner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Inc
Original Assignee
Pfizer Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Inc filed Critical Pfizer Inc
Publication of CA3043681A1 publication Critical patent/CA3043681A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA3043681A 2016-11-16 2017-11-07 Combination of an egfr t790m inhibitor and a cdk inhibitor for the treatment of non-small cell lung cancer Abandoned CA3043681A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662423146P 2016-11-16 2016-11-16
US62/423,146 2016-11-16
US201762571114P 2017-10-11 2017-10-11
US62/571,114 2017-10-11
PCT/IB2017/056952 WO2018091999A1 (en) 2016-11-16 2017-11-07 Combination of an egfr t790m inhibitor and a cdk inhibitor for the treatment of non-small cell lung cancer

Publications (1)

Publication Number Publication Date
CA3043681A1 true CA3043681A1 (en) 2018-05-24

Family

ID=60543611

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3043681A Abandoned CA3043681A1 (en) 2016-11-16 2017-11-07 Combination of an egfr t790m inhibitor and a cdk inhibitor for the treatment of non-small cell lung cancer

Country Status (6)

Country Link
US (1) US20190275049A1 (2)
EP (1) EP3541389A1 (2)
JP (1) JP2018090566A (2)
CA (1) CA3043681A1 (2)
TW (1) TW201822769A (2)
WO (1) WO2018091999A1 (2)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220280511A1 (en) * 2019-09-30 2022-09-08 Eberhard Karls Universitaet Tuebingen Medizinische Fakultaet Cdk4/6 inhibitors for the treatment of psoriasis

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL303038B2 (en) 2016-12-05 2024-08-01 G1 Therapeutics Inc Preservation of immune response during chemotherapy regimens
US11395821B2 (en) 2017-01-30 2022-07-26 G1 Therapeutics, Inc. Treatment of EGFR-driven cancer with fewer side effects
MX2020007312A (es) 2018-01-08 2021-01-08 G1 Therapeutics Inc Regimenes de dosificacion superior de g1t38.
WO2019178239A1 (en) * 2018-03-13 2019-09-19 Board Of Regents, The University Of Texas System Methods for treatment of cancers with egfr activating mutations
KR20220009446A (ko) * 2019-05-15 2022-01-24 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 비-소세포 폐암의 치료를 위한 방법 및 조성물
JP2022549272A (ja) * 2019-09-23 2022-11-24 ベータ・ファーマ・インコーポレイテッド Ｅｇｆｒ阻害剤とｃｄｋ４／６阻害剤の組み合わせを用いたｅｇｆｒ変異に関連する癌の治療
CN111557943A (zh) * 2020-04-30 2020-08-21 天津医科大学总医院 Pd0332991联合奥希替尼在制备治疗nsclc药物中的应用
US10988479B1 (en) 2020-06-15 2021-04-27 G1 Therapeutics, Inc. Morphic forms of trilaciclib and methods of manufacture thereof
EP4349340A1 (en) * 2021-06-04 2024-04-10 Mien-Chie Hung Use of pharmaceutical composition for treating lung cancer

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2251677T3 (es) 2002-01-22 2006-05-01 Warner-Lambert Company Llc 2-(piridin-2-ilamino)-pirido(2,3-d)pirimidin-7-onas.
ATE412650T1 (de) 2003-07-11 2008-11-15 Warner Lambert Co Isethionat salz eines selektiven cdk4 inhibitors
BRPI0716880A2 (pt) 2006-09-08 2013-10-15 Pfizer Prod Inc Síntese de 2-(piridin-2-ilamino)-pirido[2,3-d]pirimidin-7-onas
SI2958916T1 (sl) 2013-02-21 2018-11-30 Pfizer Inc. Trdne oblike selektivnih zaviralcev CDK4/6
UA115388C2 (uk) 2013-11-21 2017-10-25 Пфайзер Інк. 2,6-заміщені пуринові похідні та їх застосування в лікуванні проліферативних захворювань
KR20170032244A (ko) * 2014-07-26 2017-03-22 선샤인 레이크 파르마 컴퍼니 리미티드 Cdk 저해제로서 2-아미노-피리도[2,3-d]피리미딘-7(8h)-온 유도체 및 그 용도
AR104068A1 (es) * 2015-03-26 2017-06-21 Hoffmann La Roche Combinaciones de un compuesto inhibidor de fosfoinosítido 3-cinasa y un compuesto inhibidor de cdk4/6 para el tratamiento del cáncer

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220280511A1 (en) * 2019-09-30 2022-09-08 Eberhard Karls Universitaet Tuebingen Medizinische Fakultaet Cdk4/6 inhibitors for the treatment of psoriasis

Also Published As

Publication number Publication date
JP2018090566A (ja) 2018-06-14
US20190275049A1 (en) 2019-09-12
EP3541389A1 (en) 2019-09-25
WO2018091999A1 (en) 2018-05-24
TW201822769A (zh) 2018-07-01

Similar Documents

Publication Publication Date Title
US20190275049A1 (en) Combination of an EGFR T790M Inhibitor and a CDK Inhibitor for the Treatment of Non-Small Cell Lung Cancer
JP7667568B2 (ja) 複素環キナーゼ阻害剤及びその使用
RS66727B1 (sr) Kombinacija dasatiniba i adagrasiba za primenu u lečenju nesitnoćelijskog kancera pluća
CN109689047A (zh) 用于治疗癌症的药物组合
AU2014229468A1 (en) Combination of an EGFR T790m inhibitor and an EGFR inhibitor for the treatment of non-small cell lung cancer
CN110507654A (zh) 有酪氨酸激酶抑制剂的组合产品和其应用
JP2018515544A (ja) Ｅｇｆｒ変異癌を治療する方法
KR20160020502A (ko) 제약 조합물
JP7046250B2 (ja) がん処置のためのＴＧＦβ阻害剤およびＣＤＫ阻害剤の組合せ
WO2022170164A1 (en) Sulfonamides with egfr inhibition activities and their use thereof
JP2021522246A (ja) 癌治療のための併用
US12233047B2 (en) Pharmaceutical combination and use thereof
CN114430681A (zh) 使用egfr和cdk4/6抑制剂的组合治疗egfr突变相关的癌症
TWI915832B (zh) 雌激素受體降解劑及cdk4抑制劑之組合
WO2025229127A1 (en) A halogenated-heteroaryl kinase inhibitor for treating soft tissue sarcoma and vascular tumors
EP4719419A1 (en) Combinations of estrogen receptor degraders and cdk4 inhibitors
WO2025006569A1 (en) Combinations of estrogen receptor degraders and cdk7 inhibitors for the treatment of cancer
WO2025202900A1 (en) Cdk4 inhibitors for use in the treatment of mantle cell lymphoma
HK40055064A (en) Combinations of tgfb inhibitors and cdk inhibitors for the treatment of breast cancer
WO2025202854A1 (en) Cdk4 inhibitors and combinations with cdk2 inhibitors or further agents for use in the treatment of cancer
WO2024173833A1 (en) Combination of a cdk inhibitor and a flt3 inhibitor for the treatment of cancer

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20190513

FZDE Discontinued

Effective date: 20221229